Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
Browsing: Disease Area > Lung
Findings demonstrate the potential of T2-weighted MRI in dual imaging and radiotherapy systems that aim to image and treat tumors simultaneously.
Lung cancer risk assessment could be improved over existing guidelines by a four-protein biomarker blood test.
A team of researchers have developed the first comprehensive atlas of lung tumor cells.
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
NICE have approved Alecensa for use on the NHS, following positive data from a Phase II trial, including a reduced risk of brain metastasis.
The Phase III IMpower133 study has met its overall survival and progression-free survival co-primary endpoints.
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
We have brought together our top takeaways from the five days of ASCO 2018.
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.